远大医药(00512.HK)联营核心产品期取得两项重大进展
远大医药(00512.HK)公布,集团之联营公司 Sirtex Medical Pty Ltd 的核心产品SIR-Spheres钇[90Y]树脂微球近期取得两项重大进展,包括获英国国家健康照护专业组织 National Institute for Health and Care Excellence推荐用於治疗不可切除的晚期肝细胞癌成人患者,以及获美国食品药品管理局(FDA)批准开展原发性肝癌临床试验,以在美国申请原发性肝癌的上市许可,再一次证明了该产品的临床疗效和竞争优势,有助於帮助全球范围内更多肝癌患者接受SIR-Spheres钇[90Y]树脂微球治疗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.